Clinical Trial Detail

NCT ID NCT02291913
Title Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors SCRI Development Innovations, LLC
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Tamoxifen

Anastrozole + Everolimus

Fulvestrant + Everolimus

Everolimus + Letrozole

Everolimus + Toremifene

Exemestane + Everolimus

Age Groups: adult

Additional content available in CKB BOOST